2j4a: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
== | |||
==Human Thyroid hormone receptor beta ligand binding domain in complex with KB131084== | |||
<StructureSection load='2j4a' size='340' side='right' caption='[[2j4a]], [[Resolution|resolution]] 2.20Å' scene=''> | <StructureSection load='2j4a' size='340' side='right' caption='[[2j4a]], [[Resolution|resolution]] 2.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
Line 5: | Line 6: | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=OEF:3,5-DIBROMO-4-(3-ISOPROPYL-PHENOXY)BENZOIC+ACID'>OEF</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=OEF:3,5-DIBROMO-4-(3-ISOPROPYL-PHENOXY)BENZOIC+ACID'>OEF</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1bsx|1bsx]], [[1n46|1n46]], [[1nax|1nax]], [[1nq0|1nq0]], [[1nq1|1nq1]], [[1nq2|1nq2]], [[1nuo|1nuo]], [[1q4x|1q4x]], [[1r6g|1r6g]], [[1xzx|1xzx]], [[1y0x|1y0x]], [[2h6w|2h6w]], [[2nll|2nll]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1bsx|1bsx]], [[1n46|1n46]], [[1nax|1nax]], [[1nq0|1nq0]], [[1nq1|1nq1]], [[1nq2|1nq2]], [[1nuo|1nuo]], [[1q4x|1q4x]], [[1r6g|1r6g]], [[1xzx|1xzx]], [[1y0x|1y0x]], [[2h6w|2h6w]], [[2nll|2nll]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2j4a FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2j4a OCA], [http://pdbe.org/2j4a PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2j4a RCSB], [http://www.ebi.ac.uk/pdbsum/2j4a PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2j4a FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2j4a OCA], [http://pdbe.org/2j4a PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=2j4a RCSB], [http://www.ebi.ac.uk/pdbsum/2j4a PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=2j4a ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Disease == | == Disease == | ||
Line 15: | Line 16: | ||
Check<jmol> | Check<jmol> | ||
<jmolCheckbox> | <jmolCheckbox> | ||
<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/j4/2j4a_consurf.spt"</scriptWhenChecked> | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/j4/2j4a_consurf.spt"</scriptWhenChecked> | ||
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | ||
<text>to colour the structure by Evolutionary Conservation</text> | <text>to colour the structure by Evolutionary Conservation</text> | ||
Line 30: | Line 31: | ||
</div> | </div> | ||
<div class="pdbe-citations 2j4a" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 2j4a" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Thyroid hormone receptor|Thyroid hormone receptor]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
Line 36: | Line 40: | ||
[[Category: Human]] | [[Category: Human]] | ||
[[Category: Farnegardh, M]] | [[Category: Farnegardh, M]] | ||
[[Category: Alternative splicing]] | |||
[[Category: Deafness]] | [[Category: Deafness]] | ||
[[Category: Disease mutation]] | [[Category: Disease mutation]] | ||
Line 43: | Line 48: | ||
[[Category: Nuclear protein]] | [[Category: Nuclear protein]] | ||
[[Category: Nuclear receptor]] | [[Category: Nuclear receptor]] | ||
[[Category: Polymorphism]] | |||
[[Category: Receptor]] | [[Category: Receptor]] | ||
[[Category: Transcription]] | [[Category: Transcription]] | ||
[[Category: Transcription regulation]] | [[Category: Transcription regulation]] | ||
[[Category: Zinc]] | |||
[[Category: Zinc-finger]] | [[Category: Zinc-finger]] |
Revision as of 09:35, 11 July 2018
Human Thyroid hormone receptor beta ligand binding domain in complex with KB131084Human Thyroid hormone receptor beta ligand binding domain in complex with KB131084
Structural highlights
Disease[THB_HUMAN] Defects in THRB are the cause of generalized thyroid hormone resistance (GTHR) [MIM:188570]. GTHR is a disease characterized by goiter, abnormal mental functions, increased susceptibility to infections, abnormal growth and bone maturation, tachycardia and deafness. Affected individuals may also have attention deficit-hyperactivity disorders (ADHD) and language difficulties. GTHR patients also have high levels of circulating thyroid hormones (T3-T4), with normal or slightly elevated thyroid stimulating hormone (TSH).[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Defects in THRB are the cause of generalized thyroid hormone resistance autosomal recessive (GTHRAR) [MIM:274300]. An autosomal recessive disorder characterized by goiter, clinical euthyroidism, end-organ unresponsiveness to thyroid hormone, abnormal growth and bone maturation, and deafness. Patients also have high levels of circulating thyroid hormones, with elevated thyroid stimulating hormone. Defects in THRB are the cause of selective pituitary thyroid hormone resistance (PRTH) [MIM:145650]; also known as familial hyperthyroidism due to inappropriate thyrotropin secretion. PRTH is a variant form of thyroid hormone resistance and is characterized by clinical hyperthyroidism, with elevated free thyroid hormones, but inappropriately normal serum TSH. Unlike GRTH, where the syndrome usually segregates with a dominant allele, the mode of inheritance in PRTH has not been established.[19] [20] Function[THB_HUMAN] High affinity receptor for triiodothyronine.[21] Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedA new high-affinity thyroid hormone antagonist 6 with druglike properties was designed and synthesized. The compound behaved as an antagonist in a cell transactivation assay, and in a first in vivo experiment in rats. Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor.,Koehler K, Gordon S, Brandt P, Carlsson B, Backsbro-Saeidi A, Apelqvist T, Agback P, Grover GJ, Nelson W, Grynfarb M, Farnegardh M, Rehnmark S, Malm J J Med Chem. 2006 Nov 16;49(23):6635-7. PMID:17154490[22] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|